By Liz Moyer Investing.com -- Stocks were rising on a Meta-fueled tech rally that lifted the Nasdaq more than 3% on Thursday. Here are the midday movers for Feb.2. Meta Platforms...
Bristol Myers Squibb & Co (NYSE: BMY) said that its Q4 sales of $11.41 billion fell 5% Y/Y as generic competition impacted sales of its blockbuster cancer drug Revlimid in the U.S....
Bristol-Myers Squibb (BMY) reported Q4 EPS of $1.82, $0.09 better than the analyst estimate of $1.73. Revenue for the quarter came in at $11.4 billion versus the consensus estimate...
Bristol Myers Squibb came out with quarterly earnings of $1.82 per share.
The U.S. stock market is on track for its worst year since 2008, with the S&P 500 down 19.6% year-to-date. The market’s trajectory in 2023 will continue to be dictated by...
EU attempting to revive Iran nuclear deal with market staying pessimistic Crude prices could rebound from oversold conditions but stay off 2022 highs Both Iran, US likely looking...
Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. Its pharmaceutical products include chemically synthesized or small molecule drugs and products produced from biological processes, called biologics. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. It also has a pipeline of investigational medicines designed to target the common mutations associated with oncogenesis, including repotrectinib. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.
| Average | 82.22 (+10.00% Upside) |
| High | 95.00 |
| Low | 62.00 |
| Price | 74.74 |
| No. of Analysts | 18 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Buy | Strong Buy | Strong Buy | Buy |
| Technical Indicators | Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Summary | Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 0.005 | 0.005 | 0.005 | 0.00 | 0.00% | 0.00 | TSXV | |||
| 0.005 | 0.005 | 0.005 | 0.00 | 0.00% | 16.01K | TSXV | |||
| 0.01 | 0.01 | 0.01 | 0.00 | 0.00% | 0.00 | CSE | |||
| 0.005 | 0.005 | 0.005 | 0.00 | 0.00% | 154.09K | TSXV | |||
| 0.01 | 0.01 | 0.005 | 0.00 | 0.00% | 0.00 | TSXV | |||
| 0.01 | 0.015 | 0.01 | 0.00 | 0.00% | 11.25K | CSE | |||
| 0.005 | 0.01 | 0.005 | 0.00 | 0.00% | 0.00 | TSXV | |||
| 0.005 | 0.005 | 0.005 | 0.00 | 0.00% | 0.00 | TSXV | |||
| 3.89 | 3.95 | 3.84 | -0.040 | -1.02% | 545.12K | Toronto | |||
| 17.89 | 17.89 | 17.76 | 0.00 | 0.00% | 0.00 | Toronto | |||
| 0.02 | 0.02 | 0.02 | 0.00 | 0.00% | 10.00K | CSE | |||
| 0.04 | 0.04 | 0.04 | 0.00 | 0.00% | 0.00 | CSE | |||
| 23.62 | 23.62 | 23.62 | -0.13 | -0.55% | 1.10K | Toronto | |||
| 10.20 | 10.20 | 10.20 | 0.00 | 0.00% | 0.00 | Toronto | |||
| 16.59 | 17.52 | 16.47 | 0.00 | 0.00% | 0.00 | Toronto |